Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectively Surpassed milestone of more than 10,000 patients treated with CARVYKTI ® CARVYKTI now available across 294 sites worldwide;

#LEGN Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

www.stocktitan.net/news/LEGN/legend-biotech...

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025 Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a single infusion of CARVYKTI ® Translational analyses show stronger immune fitness and a more immunocompetent TME when CARVYKTI ® is used earlier in the

#LEGN Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

www.stocktitan.net/news/LEGN/legend-biotech...

#LEGN Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights

www.stocktitan.net/news/LEGN/legend-biotech...

Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting Legend Biotech (NASDAQ: LEGN) announced 10 presentations at the 67th ASH Annual Meeting, Dec 6-9, 2025 in Orlando.The program includes two oral and seven poster presentations on CARVYKTI (ciltacabtagene autoleucel) for multiple myeloma and an oral presentation of first-in-human Phase 1 data for Lucar-G39D, an allogeneic anti-CD20/CD19 dual-CAR gamma delta T cell therapy for relapsed/refractory B-cell NHL.CARVYKTI is noted as commercially available in 14 countries and used to treat more than 9,000 patients to date.

#LEGN Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

www.stocktitan.net/news/LEGN/legend-biotech...

#FUTU #PDD #SE #LEGN #TCOM #BZ #f11fc3eb-9e4a-4f85-8434-614c04dc20ca #coveragefilings

Origin | Interest | Match

Legend Biotech Achieves Record-Breaking $439M CARVYKTI Sales with Breakthrough 5-Year Survival Data CARVYKTI shows 33% progression-free survival at 5 years, while Q2 sales set CAR-T therapy record. Legend maintains $1B cash position. See full results.

#LEGN Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights

www.stocktitan.net/news/LEGN/legend-biotech...

Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting Legend Biotech announced groundbreaking 5-year survival data for CARVYKTI in multiple myeloma treatment at ASCO 2025. In the CARTITUDE-1 study, 33% of heavily pretreated relapsed/refractory multiple myeloma patients remained progression-free for 5+ years after a single CARVYKTI infusion. The study showed median overall survival of 60.7 months, with 32 of 97 patients progression-free without additional treatment. CARTITUDE-4 subgroup analyses demonstrated CARVYKTI's superior efficacy versus standard therapies across various patient groups. The company also presented promising early results from Phase 1 studies of LB1908 in gastroesophageal cancers and LB2102 in lung cancers, showcasing potential in solid tumors. Over 6,500 patients have been treated with CARVYKTI to date, marking it as the first CAR T-cell treatment in multiple myeloma to show overall survival benefit versus standard care.

#LEGN Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting

www.stocktitan.net/news/LEGN/legend-biotech...

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT Legend Biotech (NASDAQ: LEGN) announced new data presentations at ASCO, EHA, and ASGCT conferences showcasing developments in their oncology portfolio. CARVYKTI®, their lead CAR-T therapy for multiple myeloma, demonstrated impressive long-term results with patients remaining alive and progression-free for over 5 years after a single infusion in the CARTITUDE-1 study. The company has treated over 6,500 patients with CARVYKTI® to date. Additionally, CARTITUDE-4 study data showed improved survival rates compared to standard care in key subgroups. Legend will also present preliminary Phase 1 results for two pipeline candidates: LB2102 for lung cancers (licensed to Novartis) and LB1908 for gastroesophageal cancers, marking important progress in expanding cell therapy into solid tumors.

#LEGN Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT

www.stocktitan.net/news/LEGN/legend-biotech...

Legend Biotech Reports First Quarter 2025 Results and Recent Highlights Legend Biotech (NASDAQ: LEGN) reported its Q1 2025 financial results, highlighting strong performance of its flagship product CARVYKTI®. The therapy achieved $369 million in net trade sales and has treated over 6,000 patients to date. Key developments include initiating clinical production at the Tech Lane facility in Belgium, receiving positive CHMP opinion for CARVYKTI's label update, and securing TGA approval in Australia. The company maintains a strong financial position with $1.0 billion in cash and equivalents, providing runway into Q2 2026. Q1 financial results showed collaboration revenue of $185.6 million (up from $78.5M YoY), while net loss was $100.9 million. Legend Biotech expects to achieve company-wide profitability by next year, supported by manufacturing expansion and commercial execution.

#LEGN Legend Biotech Reports First Quarter 2025 Results and Recent Highlights

www.stocktitan.net/news/LEGN/legend-biotech...

Legend Biotech Turns Profitable as Cancer Drug CARVYKTI Approaches Blockbuster Status Legend Biotech achieves Q4 profitability with $26.3M earnings, driven by CARVYKTI's $963M annual sales. Strong cash position and expanded market access fuel growth momentum.

#LEGN Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

www.stocktitan.net/news/LEGN/legend-biotech...